Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Ferring Pharmaceuticals: Clinical Trials & FDA Approval Profile

Ferring Pharmaceuticals (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (4 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)14.3%
Median Closed Enrollment vs National (145 pts)288 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Ferring Pharmaceuticals
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)5 (4)
Completed vs Stopped Early13 / 3 (14.3%)
Median Closed Actual Enrollment288 participants
Physical Hospital Site Disclosure80.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Ferring Pharmaceuticals
Hospital Research SiteLocationShared Protocols
Mayo Clinic RochesterRochester, MN5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Ferring Pharmaceuticals
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06545955A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With HiPhase IIIRECRUITING
NCT06510374Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Ferring Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI